Maze Therapeutics
secret to health
Maze Corporate Presentation October 2022
view our pipeline pipeline

latest press releases

March 22, 2023
Maze Therapeutics Announces New Clinical Data Supporting MZE001 as a Potential Treatment for Pompe Disease
February 27, 2023
Maze Therapeutics Announces Positive Phase 1 Results from First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease
December 16, 2022
Maze Therapeutics Announces Completion of Phase 1 First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease

latest media coverage

December 16, 2022
Updated: Maze reveals positive first look at PhI Pompe disease candidate
June 29, 2022
LifeSci 2nd Annual Genetic Medicines Symposium 2022
March 23, 2021
Exclusive: Maze unveils their $191M pipeline, taking on Vertex and two long-sought conditions
December 7, 2020
Maze Allies With BridgeBio and Alloy to Create 2 Biotechs
December 7, 2020
Endpoints News: Maze Therapeutics Spins Out Two New Companies with Alloy and BridgeBio
January 6, 2020
Top Life Sciences Startups to Watch in 2020
February 28, 2019
Forbes: Third Rock And ARCH-Backed Genetics Startup Launches With Nearly $200 Million
February 28, 2019
Xconomy: With $191M Haul, Maze Therapeutics Takes Aim at Genetic Diseases
February 28, 2019
MIT Technology Review: The secret to a new drug could be hiding in your genes

      want to get a hold of a representative?

      Jillian Connell
      Maze Therapeutics
      jconnell@mazetx.com

      media inquires

      Katie Engleman
      1AB
      katie@1abmedia.com

      Contact Us